中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (10): 755-760.doi: 10.12144/zgmfskin202610755

• 综述 • 上一篇    

免疫靶向治疗相关白癜风研究进展

易黎1,孙睿2   

  1. 1海军特色医学中心，上海，200052；2上海交通大学医学院附属松江医院皮肤科，上海，201600
  • 出版日期:2026-10-15 发布日期:2026-10-09

Research progress in immune targeted therapy-associated vitiligo

YI Li1, SUN Rui2   

  1. 1 Naval Medical Center, Shanghai 200052, China; 2 Department of Dermatology, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201600, China
  • Online:2026-10-15 Published:2026-10-09

PDF (PC)

47

摘要： 免疫靶向治疗已广泛用于肿瘤与自身免疫性疾病，其诱发的白癜风已成为临床关注的不良事件。IL-17抑制剂、TNF-α抑制剂及免疫检查点抑制剂（ICI）虽靶点不同，但均可通过干扰Treg稳态、激活IFN-γ/JAK-STAT信号轴并募集CD8+T细胞攻击黑素细胞这一通路,诱发白癜风。本文就以上药物相关白癜风临床特征、风险分层、免疫机制与诊疗进行综述。

关键词: 免疫靶向治疗, 白癜风, 免疫检查点抑制剂, 白细胞介素17抑制剂, 肿瘤坏死因子α抑制剂, 调节性T细胞

Abstract: Immune targeted therapy is widely applied in the treatment of tumors and autoimmune diseases，and vitiligo induced by such agents has emerged as a clinically concerning adverse event.Although IL-17 inhibitors, TNF-α inhibitors and immune checkpoint inhibitors (ICIs) have distinct targets, they can all induce drug-related vitiligo by disrupting regulatory T cell (Treg) homeostasis, activating the IFN-γ/JAK-STAT signaling axis, and recruiting CD8+ T cells to attack melanocytes. This paper reviews the clinical characteristics, risk stratification, immune mechanisms, diagnosis and treatment of vitiligo associated with the above medications.

Key words: immune targeted therapy, vitiligo, immune checkpoint inhibitors, interleukin-17 inhibitors, tumor necrosis factor-α inhibitors, regulatory T cells